Immunotherapy Drugs Market is forecast to reach a value of US$ 405.7 Bn by 2028 at a CAGR of 11.5% between 2022 and 2028 | Hoffmann-La Roche AG, Merck Group

Overview:

Immunotherapy is treatment for cancer that boosts the immune system of the body. Immunotherapy is used for treating different types of cancers, it helps the body in finding cancerous cells and then destroying them. Immunotherapy drugs boost the patient’s immune system or alters the way the immune system works for treating cancer. Due to rising incidences of cancer globally there has been a rising demand for immunotherapy drugs.

The global immunotherapy drugs market is forecast to account for US$ 210.6 Billion in terms of value by the end of 2022.

Impact of Covid-19:

COVID-19 had a positive impact on the global immunotherapy drugs market, as several companies were focusing on developing vaccines or immunotherapy-based drugs for COVID-19. Immunotherapy has an important role in preventing the viral infection or even modifying the over-activated immune response against the COVID-19 virus. For instance, FDA granted a EUA (emergency use authorization) for bamlanivimab, an investigational monoclonal antibody therapy in November 2020. This can be used for treating moderate to mild COVID-19 in pediatric and adult patients. However, bamlanivimab has not been authorized for patients hospitalized owing to COVID-19 or those patients who needed oxygen therapy during the infection.

Drivers:

Increasing incidences of cancer is estimated to boost growth of the global immunotherapy drugs market over the forecast period. For instance, the Food and Drug Administration has approved a two immunotherapy drugs to be used in combination for treating patients suffering from advanced melanoma. nivolumab and relatlimab  are the two drugs which will be sold under the name of Opdualag and this combination has been approved for individuals of 12 years or above suffering from untreated melanoma which has spread in the body or has been surgically removed.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/525

Opportunities:

Rising adoption of biosimilars and monoclonal antibodies is anticipated to propel growth of the global immunotherapy drugs market over the forecast period. For instance, many immunotherapy drugs are used for treating cancer and biosimilar versions of some of these drugs are available. The biosimilars approved by the FDA can be used for treating stomach cancer, colorectal cancer, breast cancer and many others. In between 2007 and 2020, the European Medicines Agency had approved 33 biosimilars for oncology, the U.S. FDA approved 16 biosimilars, the Medical Devices Agency and the Japan Pharmaceuticals approved 10 biosimilars.

Restraints:

Rising cost of immunotherapy, production complexities, side effects of immunotherapy drugs and high attrition rate are estimated to hinder growth of the global immunotherapy drugs market over the forecast period. For instance, the cost of many immunotherapy for a single time is much higher than various long-term treatments and the number of sessions depends on the patient’s condition. Furthermore, side effects can be witnessed during and after immunotherapy sessions.

Key Takeaways:

The global immunotherapy drugs market was forecast to be valued at US$ 188.9 Billion in 2021 and is estimated to reach a value of US$ 405.7 Billion by 2028 over the forecast period.

The antibodies segment, among product monoclonal is estimated to witness robust growth in the global immunotherapy drugs market over the forecast period, owing to rising product launches and increasing approvals.

Market Trends:

1. Rising approvals by regulatory authorities is estimated to fuel growth of the global immunotherapy drugsmarket over the forecast period. For instance, nivolumab was approved by the FDA in March 2022, used for treating adults with resectable non-small cell lung cancer in neoadjuvant setting. This is the first therapy approved for neoadjuvant therapy.
2. Rising geriatric population is estimated to augment growth of the global immunotherapy drugsmarket during the forecast period. For instance, according to the World Health Organization mentioned that by 2030, 1 in 6 people will be 60 years or above of age and by 2050 older population is also anticipated to double.

Key Players:

Key players active in the global immunotherapy drugs market are Janssen Pharmaceuticals, F. Hoffmann-La Roche AG, Novartis, Merck Group, AstraZeneca, Bristol Myers Squibb and GlaxoSmithKline.

Recent Developments:

The U.S. FDA accepted the priority review of the supplemental Biologics License Application for Dupixent in May 2022, which is used during the treatment of prurigo nodularis.

GSK’s Benlysta (belimumab) gained approval from China’s National Medical Products Administration in February 2022, for treating lupus nephritis.

Keytruda, Merck’s anti-PD-1 therapy was approved by the FDA in October 2021, this is used along with chemotherapy for treating cervical cancer.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/525

Reasons to buy this Immunotherapy Drugs Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Immunotherapy Drugs market size estimation and recent advancements in the industry are explained.

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Immunotherapy Drugs Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Immunotherapy Drugs Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Immunotherapy Drugs Industry Impact

Chapter 2 Global Immunotherapy Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Immunotherapy Drugs (Volume and Value) by Type
2.3 Global Immunotherapy Drugs (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Immunotherapy Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Immunotherapy Drugs Market Analysis
Chapter 6 East Asia Immunotherapy Drugs Market Analysis
Chapter 7 Europe Immunotherapy Drugs Market Analysis
Chapter 8 South Asia Immunotherapy Drugs Market Analysis
Chapter 9 Southeast Asia Immunotherapy Drugs Market Analysis
Chapter 10 Middle East Immunotherapy Drugs Market Analysis
Chapter 11 Africa Immunotherapy Drugs Market Analysis
Chapter 12 Oceania Immunotherapy Drugs Market Analysis
Chapter 13 South America Immunotherapy Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Immunotherapy Drugs Business
Chapter 15 Global Immunotherapy Drugs Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology